Apitegromab, Muscle-directed Therapy for SMA, Put on FDA Fast Track

SMA News Today’s multimedia associate, Price Wooldridge, discusses Apitegromab being granted a fast track designation by the U.S. Food and Drug Administration.

DeAnn Runge talks about her upcoming appointment with her neurologist to discuss continuing with Evrysdi or switching back to Spinraza. She dreads making the wrong decision.

Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/